A Human NK Cell Activation/Inhibition Threshold Allows Small Changes in the Target Cell Surface Phenotype To Dramatically Alter Susceptibility to NK Cells
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
NK cell activation is negatively regulated by the expression of target cell MHC class I molecules. We show that this relationship is nonlinear due to an NK cell activation/inhibition threshold. Ewing's sarcoma family tumor cell monolayers, which were highly susceptible to NK cells in vitro, developed a highly resistant phenotype when cultured as three-dimensional multicellular tumor spheroid structures. This suggested that tumor architecture is likely to influence the susceptibility to NK cells in vivo. Resistance of the multicellular tumor spheroid was associated with the increased expression of MHC class I molecules and greatly reduced NK cell activation, implying that a threshold of NK cell activation/inhibition had been crossed. Reducing MHC class I expression on Ewing's sarcoma family tumor monolayers did not alter their susceptibility to NK cells, whereas increased expression of MHC class I rendered them resistant and allowed the threshold point to be identified. This threshold, as defined by MHC class I expression, was predictive of the number of NK-resistant target cells within a population. A threshold permits modest changes in the target cell surface phenotype to profoundly alter the susceptibility to NK cells. Whereas this allows for the efficient detection of target cells, it also provides a route for pathogens and tumors to evade NK cell attack.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further, tumor chips faithfully replicate cancer cell gene expression patterns and have the potential to also model complex cytokine and chemokine signaling networks, which may influence immune cell exhaustion and therapeutic resistance (Powers et al., 2002; Holmes et al., 2011; Marushima et al., 2011; Edmondson et al., 2014; Jensen and Teng, 2020).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Holmes et al., 2011
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Betts, M. R., Brenchley, J. M., Price, D. A., De Rosa, S. C., Douek, D. C., Roederer, M., & Koup, R. A. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00265-5 · Cited by 1,587
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1505 · Cited by 798
Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748
Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E., & Brooks, A. G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.813 · Cited by 727
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Unravelling natural killer cell function: triggering and inhibitory human NK receptors
Moretta, L., & Moretta, A. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600019 · Cited by 615
Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., & Hayday, A. C. (2005) · Nature Immunology · doi:10.1038/ni1239 · Cited by 454
Hurme, M., & Santtila, S. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199808)28:08<2598::aid-immu2598>3.0.co;2-k · Cited by 430
NK susceptibility varies inversely with target cell class I HLA antigen expression.
Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R., & Cresswell, P. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.6.1657 · Cited by 429
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
Immune-mediated dormancy: an equilibrium with cancer
Teng, M. W. L., Swann, J. B., Koebel, C. M., Schreiber, R. D., & Smyth, M. J. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.1107774 · Cited by 359
Biology of EWS/ETS fusions in Ewing's family tumors
Arvand, A., & Denny, C. T. (2001) · Oncogene · doi:10.1038/sj.onc.1204598 · Cited by 348
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host
Liu, C., Yu, S., Kappes, J., Wang, J., Grizzle, W. E., Zinn, K. R., & Zhang, H.-G. (2007) · Blood · doi:10.1182/blood-2006-09-046201 · Cited by 335
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
Doubrovina, E. S., Doubrovin, M. M., Vider, E., Sisson, R. B., O’Reilly, R. J., Dupont, B., & Vyas, Y. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6891 · Cited by 324
Joncker, N. T., Fernandez, N. C., Treiner, E., Vivier, E., & Raulet, D. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803900 · Cited by 291
Bryceson, Y. T., Ljunggren, H.-G., & Long, E. O. (2009) · Blood · doi:10.1182/blood-2009-01-201632 · Cited by 286
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.
Storkus, W. J., Alexander, J., Payne, J. A., Dawson, J. R., & Cresswell, P. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2361 · Cited by 236
Regulation of MHC Class I Assembly and Peptide Binding
Peaper, D. R., & Cresswell, P. (2008) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.24.110707.175347 · Cited by 211
Kang, H.-G., Jenabi, J. M., Zhang, J., Keshelava, N., Shimada, H., May, W. A., Ng, T., Reynolds, C. P., Triche, T. J., & Sorensen, P. H. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3259 · Cited by 184
Piontek, G. E., Taniguchi, K., Ljunggren, H. G., Grönberg, A., Kiessling, R., Klein, G., & Kärre, K. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.4281 · Cited by 168
Peptide antagonism as a mechanism for NK cell activation
Fadda, L., Borhis, G., Ahmed, P., Cheent, K., Pageon, S. V., Cazaly, A., Stathopoulos, S., Middleton, D., Mulder, A., Claas, F. H. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913745107 · Cited by 158
Harel-Bellan, A., Quillet, A., Marchiol, C., DeMars, R., Tursz, T., & Fradelizi, D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.15.5688 · Cited by 142
Shimizu, Y., & DeMars, R. (1989) · European Journal of Immunology · doi:10.1002/eji.1830190306 · Cited by 136
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways
Verhoeven, D. H. J., de Hooge, A. S. K., Mooiman, E., Santos, S. J., ten Dam, M. M., Gelderblom, H. A. J., Melief, C. J. M., Hogendoorn, P. C. W., Egeler, R. M., van Tol, M. J. D., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.016 · Cited by 125
Inhibitory Receptor Signaling via Tyrosine Phosphorylation of the Adaptor Crk
Peterson, M., & Long, E. O. (2008) · Immunity · doi:10.1016/j.immuni.2008.07.014 · Cited by 124
Kim, H. S., Das, A., Gross, C. C., Bryceson, Y. T., & Long, E. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.02.004 · Cited by 124
Lawlor, E. R., Scheel, C., Irving, J. A., & Sorensen, P. H. B. (2002) · Oncogene · doi:10.1038/sj.onc.1205053 · Cited by 100
Berghuis, D., de Hooge, A. S., Santos, S. J., Horst, D., Wiertz, E. J., van Eggermond, M. C., van den Elsen, P. J., Taminiau, A. H., Ottaviano, L., Schaefer, K., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2537 · Cited by 93
Castriconi, R., Dondero, A., Negri, F., Bellora, F., Nozza, P., Carnemolla, B., Raso, A., Moretta, L., Moretta, A., & Bottino, C. (2007) · European Journal of Immunology · doi:10.1002/eji.200737546 · Cited by 90
Positive and negative influences of regulatory T cells on tumour immunity
Gallimore, A., & Simon, A. K. (2008) · Oncogene · doi:10.1038/onc.2008.269 · Cited by 85
Meade, J. L., de Wynter, E. A., Brett, P., Sharif, S. M., Woods, C. G., Markham, A. F., & Cook, G. P. (2006) · Blood · doi:10.1182/blood-2005-03-1140 · Cited by 81
Self-citationAlmeida, C. R., & Davis, D. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6904 · Cited by 78
Pende, D., Accame, L., Pareti, L., Mazzocchi, A., Moretta, A., Parmiani, G., & Moretta, L. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199808)28:08<2384::aid-immu2384>3.0.co;2-l · Cited by 71
p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death
Myatt, S. S., Redfern, C. P. F., & Burchill, S. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2050 · Cited by 54
Missing Self, NK Cells, and The White Album
Lanier, L. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6565 · Cited by 48
Peña, J., Alonso, C., Solana, R., Serrano, R., Carracedo, J., & Ramirez, R. (1990) · European Journal of Immunology · doi:10.1002/eji.1830201113 · Cited by 47
Stam, N. J. (1990) · Lung Cancer · doi:10.1016/0169-5002(90)90302-3 · Cited by 46
Stam, N. J., Kast, W. M., Voordouw, A. C., Pastoors, L., van der Hoeven, F. A., Melief, C. J. M., & Ploegh, H. L. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.11.4113 · Cited by 41
Öhlén, C., Bejarano, M. T., Grönberg, A., Torsteinsdóttir, S., Franksson, L., Ljunggren, H., Klein, E., Klein, G. O., & Kärre, K. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.9.3336 · Cited by 40
Proteolytic Activation of the Cytotoxic Phenotype during Human NK Cell Development
Meade, J. L., Wilson, E., Holmes, T. D., de Wynter, E. A., Brett, P., Straszynski, L., Ballard, P. A. S., Trapani, J. A., McDermott, M., & Cook, G. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713829 · Cited by 21
Self-citation
Cited by
Is it time to start transitioning from 2D to 3D cell culture?
Jensen, C., & Teng, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00033 · Cited by 1,640
“This decrease in antigen presentation caused cytotoxic T lymphocyte attacks to become less likely in the cells, making it evident that 3D tumor models resemble the in vivo tumor microenvironment more accurately than 2D tumor models (Holmes et al., 2011).”
BackgroundWilson, E. B., El-Jawhari, J. J., Neilson, A. L., Hall, G. D., Melcher, A. A., Meade, J. L., & Cook, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022842 · Cited by 174
Self-citationKailayangiri, S., Altvater, B., Meltzer, J., Pscherer, S., Luecke, A., Dierkes, C., Titze, U., Leuchte, K., Landmeier, S., Hotfilder, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.57 · Cited by 142
Engineering 3D approaches to model the dynamic microenvironments of cancer bone metastasis
Qiao, H., & Tang, T. (2018) · Bone Research · doi:10.1038/s41413-018-0008-9 · Cited by 108
Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1250050 · Cited by 104
“downregulate surface MHC class I and thereby fail to bind to inhibitory NK cell receptors, further shifting the balance toward NK cell activation.(5,6) But within a multicellular tumor architecture, EwS cells can develop NK cell resistance,(6) and reports of patients”
Background
Metadata
- Authors
- Holmes, T. D., El-Sherbiny, Y. M., Davison, A., Clough, S. L., Blair, G. E., & Cook, G. P.
- Affiliations
- University of Leeds (GB)
- Corresponding author
- Davison, Adam
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-01
- Volume
- 186
- Issue
- 3
- Pages
- 1538-1545
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2095690828
- Cited by
- 52
- References
- 47
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 2 · 2016: 6 · 2015: 5 · 2014: 4 · 2013: 5 · 2012: 5
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- NK cell activation, NK cell inhibition, MHC class I, tumor spheroids, tumor architecture, NK cell resistance, NK cell evasion, NK cell cytotoxicity
- MeSH terms
- Cell Membrane, Cytotoxicity Tests, Immunologic, HeLa Cells, Humans, Immunity, Innate, Killer Cells, Natural, Lymphocyte Activation, Sarcoma, Ewing, Translocation, Genetic, Tumor Cells, Cultured, Immunophenotyping, Spheroids, Cellular, Tumor Escape, K562 Cells, Genetic Predisposition to Disease, Cell Line, Tumor, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.